Publication: Primary Immune Response Provides Protective Efficacy against SARS-CoV-2 Reinfection
| creativeworkseries.issn | JNMA Print ISSN: 0028-2715; Online ISSN: 1815-672X | |
| dc.contributor.author | Shrestha, Rupendra | |
| dc.contributor.author | Shrestha, Reena | |
| dc.contributor.author | Khadka, Ram Bahadur | |
| dc.contributor.author | Gyawali, Rabin | |
| dc.date.accessioned | 2026-02-26T04:46:23Z | |
| dc.date.available | 2026-02-26T04:46:23Z | |
| dc.date.issued | 2021 | |
| dc.description | Rupendra Shrestha Department of Ophthalmology and Visual Sciences, Albert Einstein College of Medicine, New York, United States https://orcid.org/0000-0001-6804-6070 Reena Shrestha College of Medical Science and Teaching Hospital, Bharatpur, Chitwan, Nepal https://orcid.org/0000-0001-8412-282X Ram Bahadur Khadka Department of Medical Laboratory Technology, Crimson College of Technology, Butwal, Nepal https://orcid.org/0000-0002-2763-8261 Rabin Gyawali Department of Basic Sciences, Nepal Sanjivani Institute of Health Science, Dang, Nepal https://orcid.org/0000-0002-4928-5057 | |
| dc.description.abstract | Abstract: While there is absolutely no evidence to ensure recovered patients are either likely or unlikely to get reinfected. But studies in non-human primates indicate that reinfection of recovered patients is highly unlikely. It is also clear that primary immune responses or induced immunity to severe acute respiratory syndrome coronavirus 2 remain in circulation for several months and at least temporarily confer immunity to protect from reinfection. In addition, negative virus culture analysis of re-positive suggests that positive reverse transcriptase-polymerase chain reactions in recovered patients are more likely to be false-positive, or detection of genetic remnants of virus discharged from lesions of lungs or better sampling at the time of repeat analysis. However, emerging severe acute respiratory syndrome coronavirus 2 variants are likely to be causing the infections observed in some of the recovered patients. | |
| dc.identifier | https://doi.org/10.31729/jnma.5538 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14572/4935 | |
| dc.language.iso | en_US | |
| dc.publisher | Nepal Medical Association | |
| dc.subject | COVID-19 | |
| dc.subject | immunity | |
| dc.subject | reactivation | |
| dc.subject | reinfection | |
| dc.title | Primary Immune Response Provides Protective Efficacy against SARS-CoV-2 Reinfection | |
| dc.type | Article | |
| dspace.entity.type | Publication | |
| local.article.type | Viewpoint | |
| oaire.citation.endPage | 729 | |
| oaire.citation.startPage | 727 | |
| relation.isJournalIssueOfPublication | e0f91833-5965-460d-a9c6-37f9bedfd879 | |
| relation.isJournalIssueOfPublication.latestForDiscovery | e0f91833-5965-460d-a9c6-37f9bedfd879 | |
| relation.isJournalOfPublication | e6e146a0-0ece-4aba-aa0a-6ccfbd10a12a |